$CRDL News

HC Wainwright & Co. Reiterates Buy on Cardiol Therapeutics, Maintains $9 Price Target

Cardiol Therapeutics Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx™'s Efficacy

Cardiol Therapeutics Announces Enrollment Progress And Plans To Expand Its MAVERIC Phase III Trial Evaluating CardiolRx For Risk Reduction Of Recurrence In Patients With Recurrent Pericarditis

Cardiol Therapeutics Announces Warrant Exercise for Over USD $7 Million in Proceeds

Cardiol Therapeutics: Q1 2027 Readout Will Be Make-Or-Break For Maveric

Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus Including Additional Disclosure Following Review by Staff of the Ontario Securities Commission

Cardiol Therapeutics Files $150M Base Shelf Prospectus, Enabling Future Offerings Of Shares, Debt, Warrants And Other Securities

Cardiol Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference

Cardiol Therapeutics Inc. (CRDL) is a Great Momentum Stock: Should You Buy?

Canaccord Genuity Maintains Buy on Cardiol Therapeutics, Raises Price Target to $10

Cardiol Therapeutics Advances CardiolRx in Pivotal Phase III Pericarditis Trial

Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 46th Annual Growth Conference

Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 46th Annual Growth Conference

HC Wainwright & Co. Reiterates Buy on Cardiol Therapeutics, Maintains $9 Price Target

Cardiol Therapeutics' Phase II Recurrent Pericarditis Data Published in the Journal of the American Heart Association

Cardiol Therapeutics' Phase II Recurrent Pericarditis Data Published in the Journal of the American Heart Association

Cardiol Therapeutics Announces Publication Of Phase II MAvERIC Study Results In The Journal of the American Heart Association

Cardiol Therapeutics to Participate in Fireside Chat at B. Riley Securities Mind, Muscle & Vision Summit

Cardiol Therapeutics to Participate in Fireside Chat at B. Riley Securities Mind, Muscle & Vision Summit

Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders